Neuropathic pain is a complex and debilitating condition that presents substantial challenges for effective treatment, as it often persists despite conventional therapies and can significantly impair the quality of life of affected individuals. Currently, pregabalin is the first-line treatment for neuropathic pain. However, its oral dosage form is often associated with adverse reactions such as dizziness and drowsiness, and its administration duration is limited, requiring frequent dosing. To address these issues, this study developed a hyaluronic acid (HA)-based dissolving microneedle (MN) patch incorporating poly (lactic-co-glycolic acid) (PLGA) microspheres (MS) loaded with pregabalin (PG) for peripheral administration. The MN array consists of 10 x 10 needles, covering an area of approximate to 0.5 cm2, with each needle having a height of 850 mu m. The MN patch demonstrated significant analgesic effects and sustained drug release at the application site for up to 48 h, effectively alleviating pain while minimizing dizziness and drowsiness, which are the most common side effects after systemic administration. This innovative MN platform presents a promising strategy for neuropathic pain management and provides a novel therapeutic paradigm for the peripheral application of centrally acting analgesics.